NEW YORK (GenomeWeb) – Interpace Diagnostics disclosed yesterday that it aims to raise roughly $4.3 million through the public offering of 630,000 shares of its common stock at a price of $6.81 per share.

Proceeds of the offering will be used for working capital, repayment of indebtedness, and general corporate purposes, the company said in a filing with the US Securities and Exchange Commission. Interpace said it will have approximately 2.8 million shares outstanding after the close of the offering.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.